Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 2,374,800 | 2,302,700 | 2,334,300 | 2,196,200 | 2,097,500 |
| Cost of Goods | 266,900 | 283,300 | 289,400 | 261,800 | 245,800 |
| Gross Profit | 2,107,900 | 2,019,401 | 2,044,900 | 1,934,400 | 1,851,700 |
| Operating Expenses | 1,329,800 | 986,200 | 918,600 | 828,900 | 811,600 |
| Operating Income | 779,000 | 1,033,500 | 1,126,700 | 1,106,300 | 1,040,900 |
| Interest Expense | 11,400 | 11,600 | 13,700 | 14,600 | 14,900 |
| Other Income | 123,900 | 54,900 | 63,400 | -67,300 | -71,200 |
| Pre-tax Income | 891,500 | 1,076,800 | 1,176,400 | 1,024,400 | 954,800 |
| Income Tax | 191,700 | 257,900 | 245,900 | 213,900 | 192,700 |
| Net Income Continuous | 699,800 | 818,900 | 930,500 | 810,500 | 762,100 |
| Net Income | $699,800 | $818,900 | $930,500 | $810,500 | $762,100 |
| EPS Basic Total Ops | 2.72 | 3.18 | 3.63 | 3.17 | 2.99 |
| EPS Basic Continuous Ops | 2.72 | 3.19 | 3.63 | 3.17 | 2.99 |
| EPS Diluted Total Ops | 2.69 | 3.14 | 3.59 | 3.13 | 2.96 |
| EPS Diluted Continuous Ops | 2.69 | 3.15 | 3.59 | 3.13 | 2.96 |
| EBITDA(a) | $817,800 | $1,071,900 | $1,163,400 | $1,143,600 | $1,076,800 |